ArticleJournal for immunotherapy of cancer2017

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

James W Smithy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.